How much human safety data exists for BPC-157? Three small uncontrolled reports, no randomized trials, and FDA’s stated concerns about impurities and immune reactions. What we know and what we don’t.
Last checked 6 min read · 8 sources No paid links in this article Education, not medical advice
Nobody knows BPC-157’s side-effect profile in people, because it has never been tested in a randomized controlled trial. The published human data are three small uncontrolled reports led by the same first author (16, 12 and 2 people); two reported no adverse events and the third did not describe any. FDA says compounded BPC-157 may carry a risk of immune reactions and impurities, and that it lacks enough information to know whether the drug would cause harm.
There is no randomized controlled trial of BPC-157 in people, so its side effects in humans are essentially unmeasured. A 2025 systematic review found 36 studies on its musculoskeletal use, 35 of them preclinical and 1 clinical (Vasireddi 2025). Evidence: D.
FDA says compounded BPC-157 may pose a risk of immune reactions (immunogenicity) and impurity problems, and that it lacks enough information to know whether the drug would cause harm in humans (FDA).
Recruiting now: 2 open registrations for BPC-157 in the Trial Finder.
| Study | Design | People | What was given | Adverse events reported |
|---|---|---|---|---|
| Lee & Padgett 2021 | Retrospective chart review, knee pain | 16 reached by phone (12 BPC-157 alone, 4 with thymosin beta-4) | Knee injection | None described in the abstract |
| Lee et al. 2024 | Uncontrolled pilot, interstitial cystitis | 12 women | 10 mg injected around the bladder, once | None |
| Lee & Burgess 2025 | Uncontrolled pilot, IV safety | 2 adults who had used it before | 10 mg then 20 mg IV on two days | None; no change in tested heart, liver, kidney, thyroid or glucose markers |
Sources: Lee 2021, Lee 2024, Lee 2025.
All three share the same first author and were run in private clinics; none had a placebo group, and the largest enrolled 16 people. A report of “no side effects” from a study this size cannot detect uncommon or delayed harms. Evidence: D.
A 2026 review in Sports Medicine concluded that many unapproved peptides look favorable in animal models but that rigorous human safety data are scarce, with potential for serious harm (Mendias 2026).
A 2026 review in Missouri Medicine lists the risks of unregulated injectable peptides including BPC-157: product contamination, manufacturing impurities, inaccurate dosing, pathological blood-vessel growth (angiogenesis) and possible cancer promotion (Moiz 2026). These are theoretical or mechanism-based concerns, not measured rates. Evidence: D.
The angiogenesis point comes from BPC-157’s proposed mechanism: in preclinical studies it acted on pathways involved in cell growth and blood-vessel formation (Vasireddi 2025). The same property that may help healing in animals is why reviewers flag it for people with a history of cancer.
FDA’s briefing for its July 2026 advisory meeting notes that peptides such as BPC-157 can be extremely sensitive to formulation, pH, heat and impurities, which can cause aggregation and degradation (FDA briefing document). Aggregated or impure peptides are what drive FDA’s immunogenicity concern.
Gray-market “research use only” vials are not made under drug manufacturing rules. For how labs check purity and what a certificate of analysis can and cannot tell you, see peptide contamination testing.
For the regulatory picture, read is BPC-157 legal now?, and for the broader question, are peptides safe?.
They are largely unknown in humans. Three small uncontrolled reports (16, 12 and 2 people) exist; two reported no adverse events and one did not describe any, but none had a placebo group and none was large enough to detect uncommon harms (PubMed).
Not in a randomized controlled trial. A 2025 systematic review of its musculoskeletal use found 35 preclinical studies and 1 clinical study (Vasireddi 2025).
There are no human data showing that it does or does not. Reviewers flag a theoretical concern because BPC-157 promoted blood-vessel growth pathways in preclinical studies (Moiz 2026, Vasireddi 2025).
FDA says compounded BPC-157 may pose a risk of immunogenicity and impurity problems and that it lacks sufficient information to know whether the drug would cause harm in humans (FDA).
Medical Disclaimer: This is general education, not medical advice. Researched and written by Kymata Health Editorial; sources cited inline. BPC-157 is not an FDA-approved drug. Nothing here is a recommendation to use it, and doses are described only as what a study gave. Evidence grades: A = several randomized trials or a meta-analysis; B = at least one randomized trial; C = small or pilot human data, expert consensus, or mechanism only; D = animal or cell data, or anecdote.